PRQR ProQR Therapeutics

ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer

ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer
EN
05/10/2020

Underlying

PRQRProQR Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProQR Therapeutics

 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Planned Changes to Board Composition

ProQR Announces Planned Changes to Board Composition LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company’s next Annual General Meeting (AGM) as their terms conclude.  The planned changes to ProQR’s Board composition at its 2026 AGM reflect the...

February 9, 2026 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Develo...

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohortDevelopment Candidates selected for pipeline programs AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Strategic collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, ...

January 8, 2026 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR to Participate in 8th Annual Evercore Healthcare Conference

ProQR to Participate in 8th Annual Evercore Healthcare Conference LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 8:20am ET. Webcast details will be accessible from the “Investors & Media” section of ProQR’s websi...

December 1, 2025 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Third Quarter 2025 Operating and Financial Results

ProQR Announces Third Quarter 2025 Operating and Financial Results Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagement data from all cohorts in H1 2026€ 106.9 million cash and cash equivalents as of end Q3 – providing runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company ...

November 6, 2025 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Inv...

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that following review under the new European Medicines Agency (EMA) centralized review process, the Central Committee on Research Involving Human Subjects (CCMO) has authorized ProQR’s Clinical Trial A...

October 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch